NDAOPHTHALMICSOLUTION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
RYZUMVI (phentolamine mesylate) by Septodont is soft-tissue anesthesia and the associated functional deficits is not fully understood. Approved for cardiovascular system disease. First approved in 2023.
Drug data last refreshed 20h ago
Mechanism of Action
soft-tissue anesthesia and the associated functional deficits is not fully understood. Phentolamine mesylate, the active ingredient in OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in vasodilatation when applied to vascular smooth muscle. In an animal model,…
Indications (1)
Company
Worked on RYZUMVI at Septodont? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.